Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy

NCT02570789 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

90

Enrollment

OTHER

Sponsor class

Stopped not enough accrual

Conditions

Clear-cell Metastatic Renal Cell Carcinoma

Interventions

DRUG: patients with sunitinib or pazopanib

Sponsor

Cliniques universitaires Saint-Luc- Université Catholique de Louvain